Lexaria Bioscience (LEXX) Assets Average (2012 - 2026)
Lexaria Bioscience (LEXX) posted Assets Average of $5.6 million for Q2 2026, down 10.12% sequentially from $6.3 million in Q1 2026, and down 26.92% YoY from $7.7 million in Q2 2025.
Lexaria Bioscience (LEXX) Assets Average (2012 - 2026) Analysis & Trends
Lexaria Bioscience has reported Assets Average for 15 years, with the latest figure at $5.6 million in Q2 2026.
- Quarterly Assets Average fell 26.92% year-over-year to $5.6 million in Q2 2026, while the trailing twelve-month figure through May 2026 was $5.6 million (down 26.92% YoY) and the FY2025 annual result came in at $6.5 million, up 9.13% from the prior year.
- Assets Average declined to $5.6 million in Q2 2026 per LEXX's latest filing, from $6.3 million in the prior quarter.
- Over five years, Assets Average peaked at $11.6 million in Q1 2022 and troughed at $116321.0 in Q1 2023.
- A 5-year average of $5.4 million and a median of $5.3 million in 2025 frame the typical range for Assets Average.
- The sharpest annual moves came in 2023 and 2024: Assets Average tumbled 99.0% in 2023, then jumped 2406.28% in 2024.
- Over 5 years, Assets Average stood at $4.0 million in 2022, then sank by 59.55% to $1.6 million in 2023, then soared by 480.16% to $9.3 million in 2024, then slumped by 45.2% to $5.1 million in 2025, then climbed by 10.2% to $5.6 million in 2026.
- According to Business Quant data, Assets Average over the past three periods registered $5.6 million, $6.3 million, and $5.1 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.69 Bn | 131.84 Bn | 2.84 Bn | 26.95 Bn |
| 2 | Regeneron Pharmaceuticals | 86.46 Bn | 78.47 Bn | 3.93 Bn | 41.30 Bn |
| 3 | Argenx Se | 65.62 Bn | 60.44 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.37 Bn | 53.24 Bn | 52.00 Mn | 11.22 Bn |
| 5 | BeOne Medicines | 42.17 Bn | 37.07 Bn | 1.53 Bn | 8.86 Bn |
| 6 | Alnylam Pharmaceuticals | 31.73 Bn | 28.43 Bn | 992.69 Mn | 5.34 Bn |
| 7 | BioNTech SE | 28.27 Bn | 9.87 Bn | 668.28 Mn | 25.27 Bn |
| 8 | Insmed | 27.58 Bn | 26.42 Bn | 358.27 Mn | 2.09 Bn |
| 9 | Royalty Pharma | 27.23 Bn | 26.40 Bn | - | 19.82 Bn |
| 10 | Lexaria Bioscience | 10.31 Mn | 6.70 Mn | - | 5.63 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| May 31, 2026 | 5.63 Mn |
| Feb 28, 2026 | 6.27 Mn |
| Nov 30, 2025 | 5.11 Mn |
| Aug 31, 2025 | 5.46 Mn |
| May 31, 2025 | 7.71 Mn |
| Feb 28, 2025 | 9.24 Mn |
| Nov 30, 2024 | 9.33 Mn |
| Aug 31, 2024 | 4.50 Mn |
| May 31, 2024 | 2.91 Mn |
| Feb 29, 2024 | 2.92 Mn |
| Nov 30, 2023 | 1.61 Mn |
| Aug 31, 2023 | 1.81 Mn |
| May 31, 2023 | 326,558.50 |
| Feb 28, 2023 | 116,321.00 |
| Nov 30, 2022 | 3.98 Mn |
| Aug 31, 2022 | 8.49 Mn |
| May 31, 2022 | 10.28 Mn |
| Feb 28, 2022 | 11.58 Mn |
| Nov 30, 2021 | 12.51 Mn |
| Aug 31, 2021 | 11.91 Mn |